Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1613 1614 1616 1617 1626
This examiner grants 48% of resolved cases
Ernst V. Arnold is an examiner in Tech Center 1600, with 1387 resolved cases. His allowance rate is 48.2 percent. This 48.2 percent rate indicates the frequency of granted patents among the 1387 resolved cases. Practitioners can use these figures to evaluate the prosecution environment in this tech center. The record of 1387 resolved cases provides a basis for analyzing the examiner's past actions and success rates.
The interview lift is 12.8 percent, which is a statistic that shows the change in allowance probability following an interview. This 12.8 percent lift is a metric for developing a strategy. The median days to allowance is 1164, providing a benchmark for the time required to reach a grant. This 1164-day median is a data point for managing expectations. These figures from Tech Center 1600 serve as the basis for understanding the examiner's historical performance and the duration of the prosecution cycle across a large volume of cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18884577 | LIPID COMPOSITION | Final Rejection | FUJIFILM Corporation |
| 18205399 | Hemostatic Foam | Final Rejection | STRYKER EUROPEAN OPERATIONS HOLDINGS LLC |
| 18554705 | NOVEL ANTI-INFLAMMATORY THERAPEUTICS AND METHOD OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 17831796 | Oral Care Products and Methods | Final Rejection | BASF SE |
| 17635734 | STABILIZER CONCENTRATES FOR WAX DISPERSIONS | Final Rejection | BASF SE |
| 18725289 | IONIZABLE LIPIDS FOR MULTIPLE ORGAN TARGETING | Non-Final OA | Massachusetts Institute of Technology |
| 18674730 | PREPARATION OF PHARMACEUTICAL COMPOSITIONS USING SUPERCYCLE VAPOR PHASE DEPOSITION OF METAL OXIDES | Non-Final OA | Applied Materials, Inc. |
| 18613671 | METHOD FOR COATING PHARMACEUTICAL SUBSTRATES | Final Rejection | Applied Materials, Inc. |
| 18717321 | COMPOSITION COMPRISING TWO PARTICULAR OXIDATION DYE PRECURSORS AND A PHOSPHORIC SURFACTANT | Non-Final OA | L'OREAL |
| 18679749 | HYBRID NAIL COMPOSITION | Final Rejection | L'ORÉAL |
| 18993843 | ANTIVIRUS COMPOSITE RESIN COMPOSITION WITH EXCELLENT VIRUS INACTIVATION FUNCTION AND COMPOSITE-RESIN-COATED STEEL SHEET USING SAME | Non-Final OA | POSCO CO., LTD |
| 18843771 | Materials and Methods for Treating Iron Deficiencies and Iron Chlorosis in Plants | Non-Final OA | Locus Solutions IPCo, LLC |
| 18987867 | Pearlescent Wash Composition | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18869120 | COSMETIC MATERIAL COMPOSITION AND FIBER TREATMENT COMPOSITION FOR HEAD DECORATION PRODUCTS | Non-Final OA | KAO CORPORATION |
| 18282412 | FUNCTIONALIZED CHITOSAN PREPARATION | Non-Final OA | Firmenich SA |
| 18788933 | LIPID EMULSION FOR PARENTERAL NUTRITION COMPRISING GPC | Non-Final OA | BAXTER HEALTHCARE SA |
| 17622585 | TRANSFECTION METHOD | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17755425 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | Non-Final OA | MannKind Corporation |
| 18789155 | Method of using binary coating agents in powder coating to achieve enhanced properties of the coated powder and its blends having cohesive powders | Non-Final OA | New Jersey Institute of Technology |
| 18780610 | Devices for Treating Diseases and Conditions | Non-Final OA | Tesla BioHealing Inc. |
| 18273710 | NALTREXONE COMPOSITIONS | Non-Final OA | LDN Pharma Limited |
| 17335124 | Pharmaceutical Composition for Improving Respiratory Damage and Use for Manufacturing Pharmaceutical Composition for Improving Respiratory Damage | Non-Final OA | Ming-Chien Hung |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy